» Articles » PMID: 34713356

Long COVID: Rheumatologic/musculoskeletal Symptoms in Hospitalized COVID-19 Survivors at 3 and 6 months

Overview
Journal Clin Rheumatol
Publisher Springer
Specialty Rheumatology
Date 2021 Oct 29
PMID 34713356
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To document the detailed characteristics including severity, type, and locations of rheumatic and musculoskeletal symptoms along with other COVID-19 persistent symptoms in hospitalized COVID-19 survivors at 3 and 6 months.

Methods: In this extension cohort study, two telephone surveys at 3 and 6 months following the hospitalization were carried out. In these telephone surveys, participants were asked regarding their symptoms through a previously designed standard questionnaire.

Results: At 3 months, 89.0% of survivors had at least one symptom, 74.6% had at least one rheumatic and musculoskeletal symptom, and 82.1% had at least one other COVID-19 symptom. At 6 months, 59.6% of survivors had at least one symptom, 43.2% had at least one rheumatic and musculoskeletal symptom, and 51.2% had at least one other COVID-19 symptom. Regarding the rheumatic and musculoskeletal symptoms, 31.6% had fatigue, 18.6% had joint pain, and 15.1% had myalgia; and regarding the other-COVID-19-symptoms, 25.3% had dyspnea, 20.0% had hair loss, and 17.2% sweat at 6 months. In an adjusted model, female patients were more likely to have fatigue (OR: 1.99, 95% CI: 1.18-3.34), myalgia (3.00, 1.51-5.98), and joint pain (3.39, 1.78-6.50) at 6 months.

Conclusion: Approximately 3 in 5 patients had at least one symptom with ≈2 in 5 patients had at least one rheumatic and musculoskeletal symptom. Fatigue, joint pain, and myalgia were the most frequent rheumatic and musculoskeletal symptoms. Joint pain and myalgia were mostly widespread. This information guide rheumatologists to understand the nature and features of persistent rheumatic and musculoskeletal symptoms in hospitalized COVID-19 survivors and may contribute to better management of these individuals. Key Points • Approximately 3 in 5 patients had at least one symptom with ≈2 in 5 patients had at least one rheumatic and musculoskeletal symptom at 6 months • Fatigue, joint pain, and myalgia were the most frequent rheumatic and musculoskeletal symptoms followed by back pain, low back pain, and neck pain • Dyspnea, hair loss, and sweat were the most frequent other-COVID-19-symptoms.

Citing Articles

Spatial transcriptomics of the epipharynx in long COVID identifies SARS-CoV-2 signalling pathways and the therapeutic potential of epipharyngeal abrasive therapy.

Nishi K, Yoshimoto S, Tanaka T, Kimura S, Tsunoda T, Watanabe A Sci Rep. 2025; 15(1):8618.

PMID: 40074801 PMC: 11903674. DOI: 10.1038/s41598-025-92908-7.


Global Prevalence of Long COVID, its Subtypes and Risk factors: An Updated Systematic Review and Meta-Analysis.

Hou Y, Gu T, Ni Z, Shi X, Ranney M, Mukherjee B medRxiv. 2025; .

PMID: 39830235 PMC: 11741453. DOI: 10.1101/2025.01.01.24319384.


Tracking Persistent Symptoms in Scotland (TraPSS): a longitudinal prospective cohort study of COVID-19 recovery after mild acute infection.

Sculthorpe N, Mclaughlin M, Cerexhe L, Macdonald E, Dello Iacono A, Sanal-Hayes N BMJ Open. 2025; 15(1):e086646.

PMID: 39819953 PMC: 11751823. DOI: 10.1136/bmjopen-2024-086646.


Bone Mineral Density, Bone Biomarkers, and Joints in Acute, Post, and Long COVID-19: A Systematic Review.

Alghamdi F, Mokbel K, Meertens R, Obotiba A, Alharbi M, Knapp K Viruses. 2024; 16(11).

PMID: 39599809 PMC: 11599111. DOI: 10.3390/v16111694.


Advance in the mechanism and clinical research of myalgia in long COVID.

Zhai X, Wu W, Zeng S, Miao Y Am J Clin Exp Immunol. 2024; 13(4):142-164.

PMID: 39310121 PMC: 11411160. DOI: 10.62347/TXVO6284.


References
1.
Akintayo R, Bahiri R, Miedany Y, Olaosebikan H, Kalla A, Adebajo A . African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. Clin Rheumatol. 2020; 40(9):3445-3454. PMC: 7465880. DOI: 10.1007/s10067-020-05355-2. View

2.
Kopec J, Heath A, Sayre E, Cibere J, Li L, Marra C . Prevalence of joint-specific osteoarthritis and joint pain in British Columbia, Canada. Rheumatol Int. 2021; 42(9):1623-1628. DOI: 10.1007/s00296-021-05031-x. View

3.
Kardes S, Erdem A, Gurdal H . Public interest in musculoskeletal symptoms and disorders during the COVID-19 pandemic : Infodemiology study. Z Rheumatol. 2021; 81(3):247-252. PMC: 8006118. DOI: 10.1007/s00393-021-00989-2. View

4.
Gunendi Z, Yurdakul F, Bodur H, Cengiz A, Ucar U, Cay H . The impact of COVID-19 on familial Mediterranean fever: a nationwide study. Rheumatol Int. 2021; 41(8):1447-1455. PMC: 8144686. DOI: 10.1007/s00296-021-04892-6. View

5.
Amengual O, Atsumi T . COVID-19 pandemic in Japan. Rheumatol Int. 2020; 41(1):1-5. PMC: 7671668. DOI: 10.1007/s00296-020-04744-9. View